Navigation Links
Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma
Date:5/6/2009

. The lesion is bright red and commonly referred to as a "strawberry mark".

Local complications may occur in the form of ulceration and critical localisations such as the eye area or the upper respiratory tract. These complications are the serious forms of the disease and represent 10% of total haemangioma occurrence, or 1% of births. First intention treatment is usually long-term systemic corticotherapy. The trouble with this kind of treatment is that it involves numerous and sometimes serious side-effects that are well known in infants.

About Pierre Fabre:

Pierre Fabre Laboratories, France's second biggest independent pharmaceutical laboratory, achieved a turnover of 1.75 billion euros in 2008. It employs nearly 10,000 people including 1,400 in the research sector. Its business sectors are ethical drugs, healthcare products and dermocosmetics with the brands Avene, Ducray/A Derma, Galenic/Elancyl, Klorane and Rene Furterer. Pierre Fabre Dermatologie, as part of Pierre Fabre Dermocosmetique, is specialised in prescription drugs.

In 2008, Pierre Fabre Medicament dedicated 33% of its annual turnover to R&D in five main therapeutic areas: oncology (priority sector with 50% of the overall R&D budget), Central Nervous System, cardiology, internal medicine/urology and dermatology. To find out more about Pierre Fabre Laboratories: http://www.pierre-fabre.com


'/>"/>
SOURCE Pierre Fabre SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status
2. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
3. Evotec Starts Phase II in Smoking Cessation with EVT 302
4. Synosia Starts Phase II Efficacy Trial For Rufinamide
5. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
6. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
7. Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
8. AMT Starts Collaboration With St. Jude Childrens Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
9. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
10. Gerresheimer Starts Process to Sell off its Business Segment of Technical Plastics
11. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015 /PRNewswire/ - SQI Diagnostics ... life sciences company that develops and commercializes proprietary technologies ... financial and operational results for the second fiscal quarter ... quarter the Company continued to advance business with our ... Andrew Morris , President and CEO of SQI. "The ...
(Date:5/21/2015)... Francisco, CA (PRWEB) May 21, 2015 ... sequencing, has announced a partnership with PicnicHealth, a ... for patients. Participants diagnosed with Inflammatory Bowel Disease ... well as a complementary uBiome research kit. Both ... 2014. , For more information ...
(Date:5/21/2015)... May 21, 2015  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced positive updated results ... aldoxorubicin for the treatment of unresectable glioblastoma multiforme ... open-label, multisite trial is designed to investigate the ... whose tumors have progressed following prior treatment with ...
(Date:5/21/2015)... May 21, 2015 Tunnell Consulting, ... the firm as senior statistician and Principal, a position ... experience in the management and analysis of complex and ... chemical industries. , “We’re delighted to have Julia join ... data analytics,” said Dr. Philippe Cini, Group Vice President ...
Breaking Biology Technology:SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2
... can now market product to poultry, red meat and pork processing ... ... LAWN, N.J., May 19 Tasker Products Corp.,(OTC Bulletin Board: TKER), ... today announced,that it has received authorization from the Food Safety and ...
... 19 Epeius Biotechnologies,announced today the results of an ... (Chawla et al., ASCO meeting, 2008).,Continuing on with the ... doses of Rexin-G in a Phase I safety study ... of Rexin-G given i.v. two to three times a ...
... - Shocking Lack of Global Statistics Prompts Creation of ... World Hepatitis Alliance, a newly formed Non-Governmental,Organisation, today called ... improvements in prevention, diagnosis and treatment for people living,with ... is estimated that 500 million, approximately one in 12,people, ...
Cached Biology Technology:Tasker Products Receives Authorization from USDA for its Tasker Clear for use in Meat and Pork Industries 2Tasker Products Receives Authorization from USDA for its Tasker Clear for use in Meat and Pork Industries 3ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer 2World Hepatitis Alliance Calls on Governments to Take Urgent Action to Tackle Chronic Viral Hepatitis B & C Epidemic 2World Hepatitis Alliance Calls on Governments to Take Urgent Action to Tackle Chronic Viral Hepatitis B & C Epidemic 3
(Date:5/11/2015)... DAYTON, Ohio , May 11, 2015  Through a ... Ohio had a strong showing at AUVSI,s ... . These representatives of Ohio,s UAS ... domestic and abroad from all points along the UAS ecosystem. ... Dayton Development Coalition,s (DDC) Vice President for Aerospace Rich ...
(Date:5/6/2015)... Israel , May 6, 2015 LifeBEAM, ... most established helmet producer, announced today that they will ... Helmet, the world,s first bio-sensing cycling helmet and the ... released in two new colors in order to give ... the product. In addition, LifeBEAM and Lazer announced their ...
(Date:4/21/2015)... BURNABY, Canada , April 21, 2015 ... spending and evolving government policies are boosting access control ...   According to a recently published report ... & Opportunities, 2020 ", the access control systems market ... to nearly USD1.2 billion by 2020.The access control systems ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3
... Australia's policy of restricting antibiotic use in food-producing animals ... found in its citizens, according to an article in ... available online. , Campylobacter jejuni is a leading ... resistance can make Campylobacter infections difficult for physicians to ...
... skin poxvirus from the immune system may become the key ... medical researchers at the University of Illinois at Urbana-Champaign. , ... Virology, the scientists revealed both the function of the protein ... inhibit inflammatory responses. , MC160 is so named because it ...
... study, the molecules bind to specific sites on the ... effect. In some cases, the study noted, the activation ... fourteen-fold, the greatest increase in activation ever reported for ... a protease was referred to as a state of ...
Cached Biology News:Less antibiotic use in food animals leads to less drug resistance in people, study shows 2Protein finding could lead to treatment for inflammatory diseases 2Protein finding could lead to treatment for inflammatory diseases 3Scientists develop a way to make the deadliest toxin known even more toxic 2